Observational studyThrombosis research2021
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study.
Abstract readLetterObservational Study
In one paragraph
Observational study in Thrombosis research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Is lupus anticoagulant testing with dilute Russell's viper venom clotting times reliable in the presence of inflammation?Research and practice in thrombosis and haemostasis · 2024Article
- COVID-19: Not a thrombotic disease but a thromboinflammatory disease.Upsala journal of medical sciences · 2024Review
- How to assess hypercoagulability in heparin-induced thrombocytopenia? Biomarkers of potential value to support therapeutic intensity of non-heparin anticoagulation.Thrombosis journal · 2023Article
- The Collateral Benefit of COVID Pandemic: Improved Pharmacological Venous Thromboembolism Prophylaxis Practices in Non-COVID Patients.International journal of general medicine · 2023Article
- Inherited thrombophilia: undetected comorbidity complicating COVID-19 infection.American journal of blood research · 2023Article
- Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Review
- Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.Nature reviews. Cardiology · 2022Review
- Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply 'hyperfibrinolysis'.Thrombosis research · 2022Article
- Hereditary Thrombophilia in the Era of COVID-19.Healthcare (Basel, Switzerland) · 2022Review
- Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort.Frontiers in cardiovascular medicine · 2022Article
- Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation.Frontiers in surgery · 2022Review
- Meta-Analysis and Systematic Review of Coagulation Disbalances in COVID-19: 41 Studies and 17,601 Patients.Frontiers in cardiovascular medicine · 2022Article
- Differences between surviving and non-surviving venous thromboembolism COVID-19 patients: a systematic review.Thrombosis journal · 2021Article
- How to recognize and manage COVID-19-associated coagulopathy.Hematology. American Society of Hematology. Education Program · 2021Review
- Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis.Thrombosis journal · 2021Article
- Competing Bioaerosols May Influence the Seasonality of Influenza-Like Illnesses, including COVID-19. The Chicago Experience.Pathogens (Basel, Switzerland) · 2021Article
- Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study.Thrombosis research · 2021Article
- Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction.TH open : companion journal to thrombosis and haemostasis · 2021Article
- Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications.Journal of the American College of Surgeons · 2021Review
- Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review.Journal of clinical medicine · 2021Review
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Michaël HardyUniversité catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium; Université catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
Isabelle MichauxUniversité catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium.
Sarah LessireUniversité catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
Jonathan DouxfilsDepartment of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium; Qualiblood s.a., Namur, Belgium.
Jean-Michel DognéDepartment of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.
Marion BareilleUniversité catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
Geoffrey HorlaitUniversité catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium.
Pierre BulpaUniversité catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium.
Céline ChapelleUnité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, F-42055 Saint-Etienne, France; SAINBIOSE U1059, Université Jean Monnet, University Lyon, INSERM, F-CRIN INNOVTE Network, F-42023 Saint-Etienne, France.
Silvy LaporteUnité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, F-42055 Saint-Etienne, France; SAINBIOSE U1059, Université Jean Monnet, University Lyon, INSERM, F-CRIN INNOVTE Network, F-42023 Saint-Etienne, France.
Sophie TestaHaemostasis and Thrombosis Center, Cremona Hospital, Cremona, Italy.
Hugues JacqminUniversité catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
Thomas LecompteDépartement de Médecine, Hôpitaux Universitaires de Genève, service d'angiologie et d'hémostase et Faculté de Médecine, Geneva Platelet Group (GpG), Université de Genève, Geneva, Switzerland.
Alain DiveUniversité catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium.
François MullierUniversité catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium. Electronic address: francois.mullier@uclouvain.be.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
HemostasisSARS-CoV-2AnticoagulantsBiological Variation, IndividualBlood Coagulation TestsCOVID-19C-Reactive ProteinFemaleFibrin Fibrinogen Degradation ProductsFibrinolysisHumansMalePlasminogen Activator Inhibitor 1Prospective StudiesThrombinThrombophiliaAnticoagulantsC-Reactive ProteinFibrin Fibrinogen Degradation Productsfibrin fragment DPlasminogen Activator Inhibitor 1ThrombinCOVID19D-dimersFactor VIIIFibrinogenFibrinolysisIntensive carePAI-1Thrombin generation
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.